Nucleoside analogs as potential antiviral agents for dengue virus infections

Kiroshika Pillai Veel Pilay, Malina Jasamai, Ravindran Thayan, Jacinta Santhanam, Sharifah Syed Hassan, Wei Boon Yap

Research output: Contribution to journalArticle

Abstract

Dengue virus is the causative agent of dengue fever and also the most prevalent mosquito borne viral pathogen. Up until now, treatments for dengue fever rely mainly on intensive supportive therapies. This study aimed to investigate in vitro antiviral activities of selected nucleoside analogs. These drugs were selected based on their good interactions with dengue virus replicating enzyme in a computer modeling study. The cytotoxicity of the nucleoside analogs in green monkey kidney cell line (VERO) was verified using the MTT [(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Among the drugs tested, adenovir dipivoxil exhibited toxicity to cells with only 20–40% cell viability at drug concentrations above 100 µM. Therefore, adenovir dipivoxil was omitted from the plaque reduction assay. The nucleoside analogs were further evaluated in a plaque reduction assay and ribavirin was used as a positive control. VERO cells were infected with dengue virus-2 at a multiplicity of infection of 0.4 and then treated with different concentrations of nucleoside analogs. Virus plaques were observed and counted after 7 days of incubation. The results showed that valganciclovir and stavudine inhibited dengue virus-2 replication by 6–21%. These nucleoside analogs may, therefore, have the potential to be used in treating dengue infections.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalMedicinal Chemistry Research
DOIs
Publication statusAccepted/In press - 16 Mar 2017

Fingerprint

Dengue Virus
Virus Diseases
Viruses
Nucleosides
Antiviral Agents
Dengue
Assays
Cells
Pharmaceutical Preparations
Computer viruses
Stavudine
Cercopithecus aethiops
Ribavirin
Pathogens
Cytotoxicity
Virus Replication
Infection
Culicidae
Toxicity
Cell Survival

Keywords

  • Antiviral drug
  • Dengue virus
  • MTT assay
  • Nucleoside analogs
  • Plaque assay

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Cite this

Nucleoside analogs as potential antiviral agents for dengue virus infections. / Veel Pilay, Kiroshika Pillai; Jasamai, Malina; Thayan, Ravindran; Santhanam, Jacinta; Syed Hassan, Sharifah; Yap, Wei Boon.

In: Medicinal Chemistry Research, 16.03.2017, p. 1-6.

Research output: Contribution to journalArticle

@article{62ba5a8f656341f28cfa328b588f91d5,
title = "Nucleoside analogs as potential antiviral agents for dengue virus infections",
abstract = "Dengue virus is the causative agent of dengue fever and also the most prevalent mosquito borne viral pathogen. Up until now, treatments for dengue fever rely mainly on intensive supportive therapies. This study aimed to investigate in vitro antiviral activities of selected nucleoside analogs. These drugs were selected based on their good interactions with dengue virus replicating enzyme in a computer modeling study. The cytotoxicity of the nucleoside analogs in green monkey kidney cell line (VERO) was verified using the MTT [(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Among the drugs tested, adenovir dipivoxil exhibited toxicity to cells with only 20–40{\%} cell viability at drug concentrations above 100 µM. Therefore, adenovir dipivoxil was omitted from the plaque reduction assay. The nucleoside analogs were further evaluated in a plaque reduction assay and ribavirin was used as a positive control. VERO cells were infected with dengue virus-2 at a multiplicity of infection of 0.4 and then treated with different concentrations of nucleoside analogs. Virus plaques were observed and counted after 7 days of incubation. The results showed that valganciclovir and stavudine inhibited dengue virus-2 replication by 6–21{\%}. These nucleoside analogs may, therefore, have the potential to be used in treating dengue infections.",
keywords = "Antiviral drug, Dengue virus, MTT assay, Nucleoside analogs, Plaque assay",
author = "{Veel Pilay}, {Kiroshika Pillai} and Malina Jasamai and Ravindran Thayan and Jacinta Santhanam and {Syed Hassan}, Sharifah and Yap, {Wei Boon}",
year = "2017",
month = "3",
day = "16",
doi = "10.1007/s00044-017-1863-4",
language = "English",
pages = "1--6",
journal = "Medicinal Chemistry Research",
issn = "1054-2523",
publisher = "Birkhause Boston",

}

TY - JOUR

T1 - Nucleoside analogs as potential antiviral agents for dengue virus infections

AU - Veel Pilay, Kiroshika Pillai

AU - Jasamai, Malina

AU - Thayan, Ravindran

AU - Santhanam, Jacinta

AU - Syed Hassan, Sharifah

AU - Yap, Wei Boon

PY - 2017/3/16

Y1 - 2017/3/16

N2 - Dengue virus is the causative agent of dengue fever and also the most prevalent mosquito borne viral pathogen. Up until now, treatments for dengue fever rely mainly on intensive supportive therapies. This study aimed to investigate in vitro antiviral activities of selected nucleoside analogs. These drugs were selected based on their good interactions with dengue virus replicating enzyme in a computer modeling study. The cytotoxicity of the nucleoside analogs in green monkey kidney cell line (VERO) was verified using the MTT [(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Among the drugs tested, adenovir dipivoxil exhibited toxicity to cells with only 20–40% cell viability at drug concentrations above 100 µM. Therefore, adenovir dipivoxil was omitted from the plaque reduction assay. The nucleoside analogs were further evaluated in a plaque reduction assay and ribavirin was used as a positive control. VERO cells were infected with dengue virus-2 at a multiplicity of infection of 0.4 and then treated with different concentrations of nucleoside analogs. Virus plaques were observed and counted after 7 days of incubation. The results showed that valganciclovir and stavudine inhibited dengue virus-2 replication by 6–21%. These nucleoside analogs may, therefore, have the potential to be used in treating dengue infections.

AB - Dengue virus is the causative agent of dengue fever and also the most prevalent mosquito borne viral pathogen. Up until now, treatments for dengue fever rely mainly on intensive supportive therapies. This study aimed to investigate in vitro antiviral activities of selected nucleoside analogs. These drugs were selected based on their good interactions with dengue virus replicating enzyme in a computer modeling study. The cytotoxicity of the nucleoside analogs in green monkey kidney cell line (VERO) was verified using the MTT [(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Among the drugs tested, adenovir dipivoxil exhibited toxicity to cells with only 20–40% cell viability at drug concentrations above 100 µM. Therefore, adenovir dipivoxil was omitted from the plaque reduction assay. The nucleoside analogs were further evaluated in a plaque reduction assay and ribavirin was used as a positive control. VERO cells were infected with dengue virus-2 at a multiplicity of infection of 0.4 and then treated with different concentrations of nucleoside analogs. Virus plaques were observed and counted after 7 days of incubation. The results showed that valganciclovir and stavudine inhibited dengue virus-2 replication by 6–21%. These nucleoside analogs may, therefore, have the potential to be used in treating dengue infections.

KW - Antiviral drug

KW - Dengue virus

KW - MTT assay

KW - Nucleoside analogs

KW - Plaque assay

UR - http://www.scopus.com/inward/record.url?scp=85015622737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015622737&partnerID=8YFLogxK

U2 - 10.1007/s00044-017-1863-4

DO - 10.1007/s00044-017-1863-4

M3 - Article

AN - SCOPUS:85015622737

SP - 1

EP - 6

JO - Medicinal Chemistry Research

JF - Medicinal Chemistry Research

SN - 1054-2523

ER -